Equities research analysts expect Amicus Therapeutics, Inc. (NASDAQ:FOLD) to post earnings per share of ($0.30) for the current quarter, Zacks reports. Three analysts have made estimates for Amicus Therapeutics’ earnings. The lowest EPS estimate is ($0.38) and the highest is ($0.23). Amicus Therapeutics reported earnings per share of ($0.32) in the same quarter last year, which suggests a positive year-over-year growth rate of 6.3%. The company is expected to announce its next quarterly earnings report on Wednesday, March 7th.

According to Zacks, analysts expect that Amicus Therapeutics will report full-year earnings of ($1.56) per share for the current year, with EPS estimates ranging from ($1.80) to ($1.18). For the next year, analysts forecast that the business will report earnings of ($1.12) per share, with EPS estimates ranging from ($1.88) to ($0.70). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that follow Amicus Therapeutics.

Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.10). The company had revenue of $10.90 million for the quarter, compared to the consensus estimate of $9.02 million. Amicus Therapeutics had a negative net margin of 1,092.37% and a negative return on equity of 63.54%. The company’s revenue for the quarter was up 419.0% compared to the same quarter last year. During the same period last year, the firm posted ($0.33) earnings per share.

Several equities research analysts recently issued reports on the stock. BidaskClub lowered shares of Amicus Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, December 7th. Robert W. Baird reiterated an “outperform” rating and set a $18.00 target price (up from $16.00) on shares of Amicus Therapeutics in a research report on Wednesday, October 4th. Chardan Capital reiterated a “buy” rating and set a $18.50 target price (up from $16.50) on shares of Amicus Therapeutics in a research report on Thursday, October 5th. Leerink Swann reiterated a “buy” rating and set a $20.00 target price (up from $17.00) on shares of Amicus Therapeutics in a research report on Wednesday, October 4th. Finally, J P Morgan Chase & Co restated an “overweight” rating on shares of Amicus Therapeutics in a research report on Wednesday, October 4th. One analyst has rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $17.81.

Shares of Amicus Therapeutics (NASDAQ:FOLD) traded down $0.10 during trading on Thursday, hitting $12.90. 1,493,371 shares of the company traded hands, compared to its average volume of 3,141,055. The company has a debt-to-equity ratio of 0.39, a quick ratio of 6.22 and a current ratio of 6.32. Amicus Therapeutics has a 12 month low of $4.41 and a 12 month high of $16.60.

In other Amicus Therapeutics news, insider Jay Barth sold 5,000 shares of the business’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $13.59, for a total transaction of $67,950.00. Following the completion of the sale, the insider now owns 69,184 shares in the company, valued at approximately $940,210.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO John F. Crowley sold 449,295 shares of the business’s stock in a transaction on Monday, October 16th. The shares were sold at an average price of $14.33, for a total transaction of $6,438,397.35. Following the sale, the chief executive officer now owns 380,723 shares of the company’s stock, valued at approximately $5,455,760.59. The disclosure for this sale can be found here. Insiders sold a total of 692,643 shares of company stock valued at $9,899,547 in the last quarter. 3.40% of the stock is currently owned by company insiders.

A number of hedge funds have recently made changes to their positions in FOLD. FMR LLC grew its stake in shares of Amicus Therapeutics by 3.4% in the 2nd quarter. FMR LLC now owns 21,437,508 shares of the biopharmaceutical company’s stock worth $215,876,000 after acquiring an additional 705,153 shares in the last quarter. Perceptive Advisors LLC boosted its holdings in shares of Amicus Therapeutics by 3.4% in the 3rd quarter. Perceptive Advisors LLC now owns 17,888,597 shares of the biopharmaceutical company’s stock worth $269,760,000 after buying an additional 591,925 shares during the last quarter. Redmile Group LLC boosted its holdings in shares of Amicus Therapeutics by 5.9% in the 2nd quarter. Redmile Group LLC now owns 12,043,932 shares of the biopharmaceutical company’s stock worth $121,282,000 after buying an additional 668,080 shares during the last quarter. Jennison Associates LLC boosted its holdings in shares of Amicus Therapeutics by 9.4% in the 3rd quarter. Jennison Associates LLC now owns 9,772,025 shares of the biopharmaceutical company’s stock worth $147,362,000 after buying an additional 838,267 shares during the last quarter. Finally, Vanguard Group Inc. boosted its holdings in shares of Amicus Therapeutics by 5.0% in the 2nd quarter. Vanguard Group Inc. now owns 9,118,246 shares of the biopharmaceutical company’s stock worth $91,821,000 after buying an additional 430,486 shares during the last quarter.

COPYRIGHT VIOLATION NOTICE: This news story was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of U.S. & international copyright legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/12/14/0-30-eps-expected-for-amicus-therapeutics-inc-fold-this-quarter.html.

About Amicus Therapeutics

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Get a free copy of the Zacks research report on Amicus Therapeutics (FOLD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.